Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple quiz may reveal hidden brain struggles in sickle cell patients

NCT ID NCT05347043

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the Montreal Cognitive Assessment (MoCA), a short test, can accurately screen for thinking and memory problems in adults with sickle cell disease. Researchers compared MoCA results to a full set of standard cognitive tests in 65 adults. The goal is to find a faster way to identify patients who need further evaluation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a quick, simple screening tool to detect cognitive problems in adults with sickle cell disease, enabling earlier support.
What could go wrong
This is a small, completed study (65 people) that only tests the screening tool's accuracy, not a treatment. The MoCA may not catch all cognitive issues, and results may not apply to everyone with sickle cell disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

65 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sickle cell disease, SS or SBêta0 subtypes only * Attending a consultation or a daycare hospitalization in the Tenon hospital sickle cell center * Aged 18 years old or more * Providing written informed consent * With Health Insurance Exclusion Criteria: * Obvious cognitive impairment of neurologic (e.g. previous stroke) or psychiatric origin (e.g. psychotic disorder with negative symptoms) * Insufficient French language fluency to understand the tests, inability to read and write or with no schooling beyond primary school * Anticipated unavailability in the next 6 months * Patients under supervision \& guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle cell anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease Cognitive Dysfunction sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sickle cell anemia

Contacts and locations

Locations

  • Internal Medicine Department - Tenon

    Paris, 75020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.